IL100942A0 - 2,4-diaminoquinazoline derivatives for enhancing antitumor activity - Google Patents

2,4-diaminoquinazoline derivatives for enhancing antitumor activity

Info

Publication number
IL100942A0
IL100942A0 IL100942A IL10094292A IL100942A0 IL 100942 A0 IL100942 A0 IL 100942A0 IL 100942 A IL100942 A IL 100942A IL 10094292 A IL10094292 A IL 10094292A IL 100942 A0 IL100942 A0 IL 100942A0
Authority
IL
Israel
Prior art keywords
antitumor activity
enhancing antitumor
diaminoquinazoline derivatives
diaminoquinazoline
derivatives
Prior art date
Application number
IL100942A
Other languages
English (en)
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of IL100942A0 publication Critical patent/IL100942A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
IL100942A 1991-02-20 1992-02-13 2,4-diaminoquinazoline derivatives for enhancing antitumor activity IL100942A0 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US65792291A 1991-02-20 1991-02-20

Publications (1)

Publication Number Publication Date
IL100942A0 true IL100942A0 (en) 1992-11-15

Family

ID=24639196

Family Applications (1)

Application Number Title Priority Date Filing Date
IL100942A IL100942A0 (en) 1991-02-20 1992-02-13 2,4-diaminoquinazoline derivatives for enhancing antitumor activity

Country Status (23)

Country Link
EP (1) EP0572437B1 (fr)
JP (1) JPH06500117A (fr)
KR (1) KR930703270A (fr)
CN (1) CN1064271A (fr)
AT (1) ATE121735T1 (fr)
AU (1) AU655798B2 (fr)
BR (1) BR9205645A (fr)
CA (1) CA2101542A1 (fr)
CZ (1) CZ387292A3 (fr)
DE (2) DE69202243T2 (fr)
DK (1) DK0572437T3 (fr)
ES (1) ES2071484T3 (fr)
FI (1) FI933656A (fr)
HU (1) HUT64755A (fr)
IE (1) IE920522A1 (fr)
IL (1) IL100942A0 (fr)
MX (1) MX9200675A (fr)
NO (1) NO932954L (fr)
NZ (1) NZ241627A (fr)
PT (1) PT100132A (fr)
WO (1) WO1992014716A1 (fr)
YU (1) YU17092A (fr)
ZA (1) ZA921911B (fr)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9300059D0 (en) * 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
ES2049659B1 (es) * 1992-10-08 1994-10-16 Ici Plc Una composicion farmaceutica a base de derivados de quinazolina con actividad anti-cancerigena.
GB9323290D0 (en) * 1992-12-10 1994-01-05 Zeneca Ltd Quinazoline derivatives
GB9314893D0 (en) * 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
IL112249A (en) 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
IL112248A0 (en) 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
DE4429026C2 (de) * 1994-08-16 1995-11-16 Mueller Wolfgang Inlay-Entfernungsinstrumentarium für Totalendoprothese
GB9424233D0 (en) * 1994-11-30 1995-01-18 Zeneca Ltd Quinazoline derivatives
GB9508537D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
GB9508538D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
GB9508535D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivative
AU5343096A (en) * 1995-04-27 1996-11-18 Zeneca Limited Quinazoline derivatives
GB9508565D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quiazoline derivative
WO1997020822A1 (fr) * 1995-12-01 1997-06-12 Novartis Ag Quinazolin-2,4-diazirines en tant qu'antagoniste du recepteur du neuropeptide y
GB9624482D0 (en) * 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
ES2194181T3 (es) 1996-02-13 2003-11-16 Astrazeneca Ab Derivados de quinazolina como inhibidores de vegf.
GB9603095D0 (en) * 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
GB9603097D0 (en) * 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline compounds
DK0885198T3 (da) 1996-03-05 2002-03-25 Astrazeneca Ab 4-Anilinoquinazolinderivater
GB9607729D0 (en) * 1996-04-13 1996-06-19 Zeneca Ltd Quinazoline derivatives
GB9707800D0 (en) 1996-05-06 1997-06-04 Zeneca Ltd Chemical compounds
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
NZ518028A (en) 1999-11-05 2004-03-26 Astrazeneca Ab Quinazoline derivatives as VEGF inhibitors
WO2001068615A1 (fr) * 2000-03-13 2001-09-20 Chemrx Advanced Technologies, Inc. Synthese de la quinazoline
IL151626A0 (en) 2000-04-07 2003-04-10 Astrazeneca Ab Quinazoline compounds
AU2002361846A1 (en) * 2001-12-21 2003-07-15 Bayer Pharmaceuticals Corporation Quinazoline and quinoline derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents
US8309562B2 (en) 2003-07-03 2012-11-13 Myrexis, Inc. Compounds and therapeutical use thereof
US7618975B2 (en) * 2003-07-03 2009-11-17 Myriad Pharmaceuticals, Inc. 4-arylamino-quinazolines and analogs as activators of caspases and inducers of apoptosis and the use thereof
JP2007269629A (ja) * 2004-06-21 2007-10-18 Astellas Pharma Inc キナゾリン誘導体
US20060025406A1 (en) * 2004-07-06 2006-02-02 Angion Biomedica Corporation Modulators of hepatocyte growth factor/c- Met activity
US8258145B2 (en) 2005-01-03 2012-09-04 Myrexis, Inc. Method of treating brain cancer
EP1833511A4 (fr) * 2005-01-03 2011-01-19 Myriad Genetics Inc Methode de traitement du cancer du cerveau
CA2592900A1 (fr) * 2005-01-03 2006-07-13 Myriad Genetics Inc. Composes et utilisation therapeutique associee
EP1963284A1 (fr) * 2005-12-07 2008-09-03 NeuroSearch A/S Derives innovants de la quinazoline-2,4-diamine et leur utilisation en tant que modulateurs de canaux potassiques de faible conductance actives par le calcium
CN101100466B (zh) 2006-07-05 2013-12-25 天津和美生物技术有限公司 不可逆蛋白质酪氨酸磷酰化酶抑制剂及其制备和应用
WO2008086462A2 (fr) * 2007-01-11 2008-07-17 Wyeth Dérivés de quinalozine substitués par amino en tant qu'inhibiteurs de la voie b-caténine/tcf-4 et agents de traitement du cancer
EP2173346A2 (fr) * 2007-06-27 2010-04-14 Summit Corporation Plc Utilisation de composés pour la préparation d'agents anti-tuberculose
KR20130128308A (ko) 2010-05-07 2013-11-26 캘리포니아 인스티튜트 오브 테크놀로지 이행 소포체 ａｔｐ아제의 저해를 위한 방법 및 조성물
WO2018212774A1 (fr) * 2017-05-17 2018-11-22 Vanderbilt University Composés de quinazoline utilisés en tant que modulateurs de signalisation ras

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3635979A (en) * 1969-09-29 1972-01-18 Pfizer Certain 6- and/or 7-alkoxy-substituted-2 4-bis(disubstituted amino) quinazolines
IL88507A (en) * 1987-12-03 1993-02-21 Smithkline Beckman Intercredit 2,4-diaminoquinazolines, process for their preparation and pharmaceutical compositions comprising them
AU610328B2 (en) * 1987-12-03 1991-05-16 Smithkline Beckman Intercredit B.V. 2,4- diaminoquinazoline derivatives

Also Published As

Publication number Publication date
EP0572437A1 (fr) 1993-12-08
EP0572437B1 (fr) 1995-04-26
WO1992014716A1 (fr) 1992-09-03
AU1184892A (en) 1992-09-15
HU9302384D0 (en) 1993-11-29
HUT64755A (en) 1994-02-28
ATE121735T1 (de) 1995-05-15
YU17092A (sh) 1994-12-28
DE69202243T2 (de) 1995-08-31
NZ241627A (en) 1993-06-25
AU655798B2 (en) 1995-01-12
CA2101542A1 (fr) 1992-08-21
KR930703270A (ko) 1993-11-29
JPH06500117A (ja) 1994-01-06
CZ387292A3 (en) 1994-04-13
DE9290018U1 (de) 1993-10-14
ES2071484T3 (es) 1995-06-16
FI933656A0 (fi) 1993-08-19
IE920522A1 (en) 1992-08-26
PT100132A (pt) 1993-05-31
MX9200675A (es) 1992-08-01
ZA921911B (en) 1993-08-19
DK0572437T3 (da) 1995-07-03
NO932954D0 (no) 1993-08-19
BR9205645A (pt) 1994-06-07
DE69202243D1 (de) 1995-06-01
FI933656A (fi) 1993-08-19
CN1064271A (zh) 1992-09-09
NO932954L (no) 1993-08-19

Similar Documents

Publication Publication Date Title
IL100942A0 (en) 2,4-diaminoquinazoline derivatives for enhancing antitumor activity
GR3017122T3 (en) Quinazolines derivatives for enhancing antitumor activity.
DE69716135D1 (en) In 6-position durch thio substituierte paclitaxele
EP0659209A4 (fr) Therapie du cancer faisant appel a des cellules malignes.
GR3032723T3 (en) 10-desacetoxytaxol derivatives.
IN170909B (fr)
ZA922815B (en) Pyrimidine derivatives for enhancing antitumor activity
TW282455B (fr)
CA1265159C (fr) Gem-dihalogeno-1,8-diamino-4-aza-octanes
EP0654995A1 (fr) Derives de 4-oxa-1-azabicyclo (3,2,0) heptan-7-one utilises comme agents antitumoraux.
RU93054001A (ru) 2,4-диаминохиназолиновые производные, способ их получения фармацевтическая композиция, способ ингибирования р-гликопротеина
CA1265160C (fr) Gem-dihalogeno- et gem-tetrahalogeno-1,12-diamino-4, 9-diaza-dodecanes